QGEN - Qiagen N.V.
After hours:
| Previous close | 45.78 |
| Open | 46.34 |
| Bid | 45.53 x 800 |
| Ask | 47.39 x 1400 |
| Day's range | 46.27 - 46.63 |
| 52-week range | 40.38 - 51.18 |
| Volume | |
| Avg. volume | 825,474 |
| Market cap | 10.599B |
| Beta (5Y monthly) | 0.38 |
| PE ratio (TTM) | 29.79 |
| EPS (TTM) | 1.56 |
| Earnings date | 25 Jul 2023 - 31 Jul 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 53.98 |
ZacksQiagen (QGEN) Down 0.6% Since Last Earnings Report: Can It Rebound?
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ZacksQIAGEN (QGEN) Expands Enzyme Offering to Aid Laboratory
QIAGEN is a one-stop shop for all research needs, including solutions for sample preparation, automation and bioinformatics with enzyme offering expansion.
ZacksHere's Why You Should Retain QIAGEN (QGEN) Stock for Now
QIAGEN (QGEN) is likely to benefit from high organic growth across its non-COVID-19 product group and portfolio advancements, reflecting a positive share price movement.
ZacksQiagen (QGEN) Q1 Earnings Top Estimates, Operating Margin Down
Amid an uncertain macroeconomic environment, Qiagen's (QGEN) first-quarter results reflect an impressive organic top line, led by strength in non-COVID-19 product groups.
ZacksQiagen (QGEN) Q1 Earnings Beat Estimates
Qiagen (QGEN) delivered earnings and revenue surprises of 8.51% and 0.09%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireQIAGEN exceeds outlook for Q1 2023 with 12% CER sales growth in non-COVID product portfolio
Q1 2023: Net sales of $485 million (-23% at actual rates, -20% at constant exchange rates, CER); diluted EPS of $0.37 and adjusted diluted EPS of $0.51 // Net sales at CER of $502 million ahead of outlook for at least $490 million CER and adjusted diluted EPS of $0.52 CER ahead of outlook for at least $0.47 CER // 12% CER sales growth in non-COVID product portfolio to $434 million, while COVID product sales decline 76% to $52 million // Full-year 2023 outlook reaffirmed for at least $2.05 billio
GlobeNewswireQIAGEN welcomes U.S. Preventive Services Task Force reaffirmation for latent TB screening in populations at increased risk
Venlo, the Netherlands, and Germantown, Maryland, May 03, 2023 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it welcomed the U.S. Preventive Services Task Force (USPSTF) reaffirming a previously issued recommendation for latent tuberculosis infection (LTBI) screening by primary care physicians in populations at increased risk. The USPSTF issued a final report on May 2 to continue the “B” recommendation for screening of these populations, building on
ZacksWill Qiagen (QGEN) Beat Estimates Again in Its Next Earnings Report?
Qiagen (QGEN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Simply Wall St.Is Weakness In Qiagen N.V. (NYSE:QGEN) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
It is hard to get excited after looking at Qiagen's (NYSE:QGEN) recent performance, when its stock has declined 10...
GlobeNewswireQIAGEN launches QIAstat-Dx in Japan with respiratory panel for syndromic testing
Japan to become the latest of more than 100 countries where QIAstat-Dx is available for molecular testing in diagnosing over 20 respiratory diseases from one patient sample // Generates actionable results in about one hour based on PCR technology, unique ability to provide Ct values and easy access to amplification curves to support clinical decisions // More than 3,500 QIAstat-Dx instruments installed worldwide at the end of 2022Venlo, the Netherlands, April 24, 2023 (GLOBE NEWSWIRE) -- QIAGEN
GlobeNewswireQIAGEN announces expansion of Supervisory Board
Steve Rusckowski has joined Supervisory Board and will stand for election at Annual General Meeting in June 2023Venlo, the Netherlands, April 20, 2023 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Steve Rusckowski, an internationally recognized healthcare industry executive and former Chairman, President and CEO of Quest Diagnostics, has joined the Supervisory Board as a new member and will stand for election at the next Annual General Meeting schedu
ZacksWill Solid Biosciences Inc. (SLDB) Report Negative Q1 Earnings? What You Should Know
Solid Biosciences Inc. (SLDB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksEarnings Preview: Qiagen (QGEN) Q1 Earnings Expected to Decline
Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
QIAGEN showcases latest technologies to advance cancer research at AACR Annual Meeting 2023
Launch of cell-free DNA (cfDNA) next-generation sequencing kits to test liquid biopsies // Study to demonstrate QIAGEN’s expertise in detecting disease-relevant cfDNA mutations // New pan-cancer panels for digital PCR platform QIAcuity to be launched in fall 2023Venlo, the Netherlands, April 14, 2023 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of QIAseq Targeted cfDNA Ultra Panels that will enable researchers studying cancer and other disease
ZacksQIAGEN's (QGEN) Expanded Test Menu Aids, FX Woe Lingers
In terms of QIAstat-Dx, QIAGEN (QGEN) continues to witness increased demand for system placements and growing consumables usage around the world.
ZacksQIAGEN (QGEN) QIAxcel Connect Gets Red Dot Design Award
QIAGEN (QGEN) QIAxcel Connect automates the analysis of the size and quality of isolated DNA and RNA.
- GlobeNewswire
QIAGEN’s QIAxcel Connect wins Red Dot design award
International design competition recognizes high-resolution DNA or RNA capillary electrophoresis instrument // QIAxcel marks the fourth QIAGEN instrument to receive Red Dot award, highlights strategy of upgrading portfolio to add new features – in particular wireless connectivity // QIAxcel Connect offers scientists many benefits for nucleic acid analysis with minimal handling time, flexible throughput and speedVenlo, the Netherlands, March 29, 2023 (GLOBE NEWSWIRE) -- QIAGEN today announced tha
- Simply Wall St.
With 83% ownership, Qiagen N.V. (NYSE:QGEN) boasts of strong institutional backing
Key Insights Significantly high institutional ownership implies Qiagen's stock price is sensitive to their trading...
ZacksTango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates
Tango Therapeutics, Inc. (TNGX) delivered earnings and revenue surprises of 8.33% and 2.86%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireQIAGEN receives approval for its net-zero carbon emissions target by Science Based Targets initiative (SBTi)
SBTi has validated the QIAGEN targets to reach net-zero greenhouse gas (GHG) emissionsVenlo, The Netherlands, March 27, 2023 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its emissions reduction targets have been validated by the Science Based Targets initiative (SBTi) – a global recognition of its ambitions to honor the Paris Agreement’s climate goals. The SBTi is a global body that enables companies to set ambitious emissions reductions target
- Business Wire
QIAGEN Announces Form 20-F Annual Report Filing for 2022 Results
VENLO, The Netherlands, March 13, 2023--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2022, with the U.S. Securities and Exchange Commission. The document can be accessed on QIAGEN’s website here.
- Zacks
QIAGEN (QGEN) to Develop CDx Test for TIBSOVO With New Pact
QIAGEN (QGEN) will develop a real-time in vitro PCR test that can be utilized to spot IDH1 gene mutations in AML patients in whole blood and bone marrow aspirates.
- Business Wire
QIAGEN and Servier Partner to Develop Companion Diagnostic for Acute Myeloid Leukemia (AML) Therapy Drug
VENLO, the Netherlands, March 09, 2023--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has entered into a strategic partnership with Servier, a global pharmaceutical group, to develop a companion diagnostic test for TIBSOVO®, an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of the blood cancer acute myeloid leukemia (AML).
ZacksBD (BDX) Boosts Molecular Diagnostics Portfolio With New Tests
Recent developments in the Molecular Diagnostics space have been aiding key MedTech players like BD (BDX) to boost their business.
- Business Wire
QIAGEN and SOPHiA GENETICS Forge Partnership to Combine Strengths in Next-Generation Sequencing
VENLO, Netherlands, March 01, 2023--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the new QIAseq Platform Partnership program and the first partnership with medical data-analysis provider SOPHiA GENETICSTM (Nasdaq: SOPH) that will bring together its QIAseq reagent technology for next-generation sequencing (NGS) with the SOPHiA DDMTM digital analytics platform.